----item----
version: 1
id: {09D6196B-7390-4515-B428-78F0FAD7E01A}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/MainStory/2008/03/07/SC00000014
parent: {BCCB7F31-A968-4BC1-B2F8-032CE1B9D3D3}
name: SC00000014
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: d57888c5-fe18-4ed9-96b6-79972500d0b8

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 38

{9557EF58-727F-4007-9C73-6232F381DFF1}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 45

US FDA approves J&J's Concerta for adult ADHD
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 10

SC00000014
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 975

<p>Johnson & Johnson's Concerta (methylphenidate) extended-release tablets have been approved by the US FDAfor use in adult attention-deficit hyperactivity disorder (ADHD).</p><p>The approval, for the once-daily treatment of adults aged 18-65 years with doses of 18-72mg, was based on the 229-patient 02-159 Phase III trial, results of which were presented at last year's AACAP (American Academy of Child and Adolescent Psychiatry) conference. Concerta was previously indicated for use in children and adolescents aged 6-17 years. The product uses the company's OROS delivery system.</p><p>Johnson & Johnson said that ADHD is thought to affect one in 20 adults in the US. Other anti-ADHD therapies on the market for adults include Lilly's Strattera (atomoxetine, which was the first to be approved specifically for adult use), Shire's Adderall XR (mixed amphetamine salts) and Vyvanse (lisdexamfetamine dimesylate) and Novartis/Celgene's Focalin XR (dexamethlyphenidate).</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 10

SC00000014
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20080307T000000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20080307T000000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20080307T000000
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 45

US FDA approves J&J's Concerta for adult ADHD
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{FA402FE3-10BE-4593-960E-5A51D6FEF17A}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 3

638
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160119T221708Z
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

d57888c5-fe18-4ed9-96b6-79972500d0b8
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160119T221708Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 14

sitecore\admin
